French Biologics CDMO: Manufacturers Guide (2026)

A French biologics CDMO is a contract development and manufacturing organisation specialising in monoclonal antibodies, recombinant proteins, biosimilars and biologics fill-finish for external biotech and biopharma clients. The cluster is built around GTP Bioways (now part of Olon), Cenexi, Recipharm France, Fareva and a tier of mid-sized specialists. France 2030 and the EU Critical Medicines Act are reshaping their pipeline, but most still chase clients through CPHI booths and partnership tracks that scale poorly.

How Big the French Biologics CDMO Engine Really Is

France is the fifth-largest pharmaceutical market in the world and the second in Europe, with 47.1% of pharmaceutical turnover coming from exports, according to LEEM, the French pharma trade body. The country runs roughly 300 pharmaceutical production sites and was the European leader in pharmaceutical production for several years before being overtaken. The biologics share of that output has lagged. LEEM has repeatedly flagged that only a small fraction of newly approved innovative treatments are produced domestically, which is the gap the current CDMO build-out is meant to close.

The French CDMO segment is set to grow faster than the European average. Towards Healthcare projects France to expand at a 7.9% CAGR, the fastest in Europe, against a continent-wide pharma CDMO base of USD 37.98 billion in 2025. Globally, the biologics CDMO category is moving even harder. Precedence Research values biologics CDMO at USD 23.08 billion in 2025, climbing to USD 55.11 billion by 2035 at a 9.14% CAGR.

The structural opportunity for French CDMOs is twofold. First, EU sponsors are reshoring biologics supply away from Asia under the new regulatory regime. Second, France is the only large EU country with a sovereign pharmaceutical investment programme of this size aimed specifically at biologics.

The Companies That Anchor the French Biologics CDMO Cluster

GTP Bioways (Toulouse, Labège, Veyre-Monton, Saint-Julien-en-Genevois) is the most recognisable independent French biologics CDMO. Olon Group acquired GTP Bioways in 2024, folding four French facilities into Olon’s CDMO network. GTP’s capability set spans monoclonal antibodies, antibody-drug conjugates, recombinant proteins, enzymes and nanodrugs across mammalian, microbial, yeast and insect cell expression systems, plus analytical and fill-finish support. The company invested EUR 12 million in two new GMP production units in Toulouse, including a 300L microbial line and a 10L mammalian cell unit, described in the Olon France announcement. As Paolo Tubertini, CEO of Olon, put it on the acquisition, “the acquisition of GTP Bioways Group implies a strong and significant strengthening of Olon’s service pipeline with the aim of creating new business opportunities.”

Cenexi (Fontenay-sous-Bois) is the French fill-finish anchor and a rising biologics specialist. The Fontenay-sous-Bois site, described on Cenexi’s own site, is a 15,000 m² GMP plant on a four-hectare site nine kilometres east of Paris, with 670 employees and a production capacity of 300 million injectable ampoules per year across 1ml to 25ml formats. Sterile and injectable products already account for 70% of Cenexi revenue, with the company guiding to 80% within three years and an increasing share coming from biologics including monoclonal antibodies, antibody-drug conjugates and peptides. Cenexi is the closest thing France has to a dedicated mid-sized biologics fill-finish play.

Recipharm France sits inside the wider Recipharm CDMO group headquartered in Stockholm with sites across France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the US. The biologics arm, ReciBioPharm, builds out advanced therapy medicinal products including viral vectors, mRNA, plasmid DNA and live-microbial biopharmaceuticals, and reported a record first half in 2025 on the back of an end-to-end service model.

Fareva is the largest contract manufacturer in France and one of the top five pharma CMOs worldwide. Fareva picked up two biologics facilities from Pierre Fabre in 2020: an oncology injectable plant in Pau and a monoclonal antibody plant in Saint-Julien-en-Genevois on the French-Swiss border. The company is named alongside Lonza, Sandoz and Catalent in the most recent Biologics Fill Finish Services market report covering 2025 to 2035.

Delpharm and a long tail of specialty CDMOs (Bio-Sourcing, ABL, Polyplus) round out the cluster, alongside in-house Sanofi capacity that does not directly compete for external CDMO work.

Why France 2030 and the Critical Medicines Act Change the Demand Picture

Two policy moves are doing the heavy lifting on French biologics CDMO demand into 2026 and beyond.

France 2030 bioproduction. The France 2030 plan allocates roughly EUR 7.5 billion to the health sector under Plan Santé 2030, with around EUR 1 billion dedicated to bioproduction and an explicit ambition to make France a top-three European bioproduction hub. The programme funds CDMOs and sponsors directly. Igyxos Biotherapeutics, for example, secured a EUR 5.7 million grant under the France 2030 “Biotherapies and Bioproduction of Innovative Therapies” call. These grants feed contract demand into French CDMOs because most laureates need external GMP capacity.

Sanofi’s own EUR 2 billion-plus biologics build. Sanofi announced on May 13 2024 that it would invest more than EUR 1 billion to build a new Vitry-sur-Seine facility that doubles the site’s monoclonal antibody production capacity, with nearly EUR 500 million in Neuville-sur-Saône for an evolutive biological drugs and vaccines facility launching in 2025. On top of that, Sanofi added EUR 40 million to its Lyon Gerland bioproduction site in November 2024, with more than EUR 15 million tagged for internalising preclinical and clinical mAb production. The headline is captive, but the second-order effect feeds independent CDMOs: when a national champion crowds the bioproduction labour market and capex pipeline, mid-sized sponsors look to French CDMOs to secure parallel capacity.

EU Critical Medicines Act. On 12 May 2026 the European Parliament and Council reached a provisional deal on the Critical Medicines Act. EMA Executive Director Emer Cooke noted the agreement “marks a significant milestone towards strengthening Europe’s capacity to improve the availability, supply and production of critical medicines.” The Act combines regulatory tools with industrial policy measures to address structural vulnerabilities in EU pharmaceutical supply, with biologics, APIs and biosimilars among the categories the European Commission has flagged for prioritisation. EU sponsors evaluating CDMO partners now have a regulatory tailwind for placing biologics programmes inside the EU rather than offshoring them.

Eric Devic, CEO of GTP Tech, put it plainly in BioProcess International: “France, as did many countries, realized with the COVID crisis that the bioproduction capacities were not able to meet the demand.” That realisation is now the policy.

What Sponsors Are Buying in 2026

Three buying patterns are emerging from biotech and biopharma sponsors approaching French CDMOs in 2026.

Monoclonal antibody clinical to Phase II programmes. Mid-sized European biotechs with mAb assets prefer EU-based CMC partners under the new regulatory regime. French CDMOs are well-positioned for preclinical through Phase II, the exact bracket GTP Bioways and several specialty players target.

Biologics fill-finish under capacity constraints. GLP-1 receptor agonists are absorbing aseptic fill-finish capacity globally. The displacement effect is rerouting non-GLP-1 biologics to facilities like Cenexi Fontenay-sous-Bois and Fareva Pau for 2027 to 2028 slots.

Biosimilars and second-source manufacturing. The Critical Medicines Act encourages biosimilar production as a cost-effective alternative to originator drugs facing patent cliffs. French CDMOs with mammalian expression and analytical capability are prime candidates for these contracts.

The buying signal moves faster than the trade fair calendar. By the time a sponsor’s procurement lead walks the CPHI floor in Frankfurt, the Phase II slot they needed has been allocated.

Why Conventional Sales Channels Are Falling Short

French biologics CDMOs have leaned on a familiar set of channels for two decades. Each is hitting a structural ceiling.

Trade fairs. CPHI Worldwide, BIO International Convention, BIO-Europe and the World ADC Conference remain the default rallying points. CPHI Worldwide 2025 in Frankfurt drew roughly 2,400 exhibitors and over 62,000 visitors. Booths and partner tracks run EUR 15,000 to EUR 60,000+ before travel, staffing, hospitality and follow-up. The arithmetic is now well-known to French CDMO BD teams: cost per qualified lead lands between EUR 300 and EUR 900+, and it gets worse every year as the same competitors crowd the same aisles in front of the same procurement leads.

Partnership tracks at biotech congresses. BIO-Europe and J.P. Morgan Healthcare partnering systems route sponsors to one-on-one meetings. Useful for relationship maintenance, weak for net-new pipeline. Slots fill with existing relationships before mid-sized French CDMOs get on the calendar.

Scientific advisors and KOL networks. French CDMOs traditionally use academic and KOL relationships to open biotech doors. The channel is real but does not scale. Each KOL covers a narrow therapeutic area. You cannot KOL your way into 200 target sponsors at once.

Direct pharma BD outreach. Senior BD leads with biologics CMC fluency cost EUR 150,000 to EUR 220,000 fully loaded in France, before booking a single qualified meeting. Covering EU, UK, US East, US West and Switzerland needs four or five hires with very different language and regulatory expertise. Cost per qualified lead: EUR 500 to EUR 1,200+.

Trade press and broker networks. French Healthcare promotion, BioPharm International placements and pharma brokers still pull a small share of leads. Margins erode by 20 to 35% through brokers, and trade press rarely converts to pipeline.

Cold calling across borders. Engaging a biologics buying committee takes 20+ touches per account in the sponsor’s native business language, with credibility on mammalian platforms, single-use systems, audit history, CEP and DMF filings. Native French, German, English, Italian, Spanish and Mandarin speakers who also understand bioprocess intensification are nearly impossible to hire and retain.

Government trade missions. Business France and French Healthcare delegations are useful first exposure but run on fixed annual calendars and cannot replace continuous, signal-driven pipeline.

The structural problem is shared. These channels reach one person at a time in an industry where the CDMO selection decision involves five to eleven stakeholders across CMC, quality, regulatory affairs, supply chain and procurement.

The AI Outbound Alternative for French Biologics CDMOs

A modern AI-powered outbound engine addresses the structural problem directly. It reaches whole buying committees at hundreds of biotech and biopharma sponsors at the same time, in their native business language, triggered by real buying signals, with role-specific technical context attached to every message.

Multi-threaded outreach to the full buying committee

A typical biologics CDMO selection involves the CMC lead, head of biologics development, quality director, regulatory affairs lead, supply chain manager and procurement. AI outbound engages all of them in parallel. The CMC lead sees your single-use mammalian platform and clone performance. The quality director gets your audit and inspection history. Regulatory affairs receives your CEP and DMF references. Procurement gets the commercial framing.

Signal detection for accurate timing

The system monitors signals indicating a sponsor is about to need a CDMO partner:

• Phase II readouts and Phase III initiations (sponsor needs commercial-scale partners 12 to 18 months out)
• New IND and CTA filings (sponsor needs clinical supply at GMP scale)
• Patent cliffs on originator biologics (biosimilar developers need API and finished-product CDMO capacity)
• Capacity announcements from competitor CDMOs (sponsors evaluating alternatives)
• Series B and Series C raises in biologics (sponsor budget is unlocking)

Native-language depth in seven markets

A single engine fields professional native French, German, English, Italian, Spanish, Dutch and Mandarin outreach. That replaces five or six separate BD hires per region and turns French CDMOs into credible counterparts in markets they would otherwise reach only through brokers.

Cost and scalability that compounds

Trade fairs cost EUR 300 to EUR 900+ per qualified lead and scale linearly. Field BD reps cost EUR 500 to EUR 1,200+ and scale worse than linearly. A papaverAI engine starts at USD 150 to USD 300 per qualified lead and gets cheaper over time. The longer it runs, the more it learns which signals predict booked meetings.

Traditional channels have a ceiling. AI outbound has a compounding floor.

What This Means for a French Biologics CDMO BD Director in 2026

If you run BD at GTP Bioways, Cenexi, Recipharm France, Fareva, Delpharm or a specialty French biologics CDMO, the question for the next six quarters is straightforward: how do you turn France 2030 funding and the Critical Medicines Act tailwind into booked capacity, before competitors in Switzerland, Germany, Italy and Ireland do the same?

You can keep buying CPHI booths, hire two more senior BD leads and hope partner tracks convert. Or you can run a parallel system that reaches the full biologics buying committee at hundreds of sponsors, triggered by Phase II readouts, IND filings and competitor capacity announcements, at one third the cost per qualified lead.

The French CDMOs that will own the reshoring wave are the ones building this engine now, not the ones waiting to see Sanofi or Recipharm headline numbers in 2027.

To discuss what a signal-driven engine could look like for your CDMO, contact us or read how it works. For broader context, see our French pharma and biotech exporters guide and the related Swiss biologics CDMO manufacturers post.

FAQ

What is a French biologics CDMO?

A French biologics CDMO is a contract development and manufacturing organisation based in France that develops and manufactures biologic drugs for external biotech and biopharma sponsors. Categories include monoclonal antibodies, recombinant proteins, antibody-drug conjugates, biosimilars and biologics fill-finish. Key players are GTP Bioways (Olon), Cenexi, Recipharm France and Fareva.

How big is the French biologics CDMO market?

France is the fifth-largest pharmaceutical market globally and the second in Europe. The French pharma CDMO segment is projected to grow at 7.9% CAGR, the fastest in Europe, against a continent-wide base of USD 37.98 billion in 2025. The global biologics CDMO category is on track from USD 23.08 billion in 2025 to USD 55.11 billion by 2035.

How does France 2030 affect biologics CDMOs?

France 2030 dedicates around EUR 1 billion to bioproduction, with grants flowing to sponsors and CDMOs. Most laureates need external GMP capacity, which feeds contract demand into French CDMOs. The programme is paired with Sanofi’s own EUR 2 billion-plus French biomanufacturing investment, which crowds the labour market and pushes sponsors toward independent CDMOs for parallel capacity.

What does the EU Critical Medicines Act mean for biologics manufacturing in France?

The Critical Medicines Act, on which the European Parliament and Council reached a provisional deal on 12 May 2026, encourages EU-based production of critical medicines including biologics, APIs and biosimilars. EU sponsors now have a regulatory tailwind for placing biologics programmes inside the EU rather than offshoring them, which directly benefits French CDMOs with available capacity.

Why are trade fairs and partnership tracks less effective for French biologics CDMOs?

Trade fairs and partnership tracks at BIO-Europe and BIO International reach one person at a time in an industry where CDMO decisions involve five to eleven stakeholders. Cost per qualified lead runs EUR 300 to EUR 900+ at fairs and EUR 500 to EUR 1,200+ for field BD. AI-driven outbound reaches the full buying committee in parallel at USD 150 to USD 300 per qualified lead.